Clinical Outcomes of Patients With Carbapenemase-Producing Escherichia coli (CP-Ec) Infection
| . | Total Patients (N = 57) . | MBL-Ec (n = 19) . | Non–MBL-Ec (n = 38) . | P (α = 0.05)a . |
|---|---|---|---|---|
| Clinical response | 39 (68%) | 14 (74%) | 25 (66%) | .76 |
| Disposition after dischargeb | .06 | |||
| Home | 38 (67%) | 16 (84%) | 22 (58%) | |
| Other care facility | 5 (9%) | 2 (11%) | 3 (8%) | |
| Hospice or death | 14 (25%) | 1 (5%) | 13 (34%) | |
| Time from culture to discharge, median days (Q1, Q3) | 18 (7, 25) | 21 (6, 54) | 17.5 (8, 24) | .35c |
| 30-Day mortality | 10 (18%) | 0/19 (0%) | 10/38 (26%) | .02 |
| 90-Day mortality | 15 (26%) | 0/19 (0%) | 15/38 (39%) | .001 |
| DOOR outcomes (30 d) | 62.0% (48.2%-74.3%)d | |||
| Alive without events | 25 (44%) | 10 (53%) | 15 (39%) | |
| Alive with 1 event | 11 (19%) | 4 (21%) | 7 (18%) | |
| Alive with 2 or 3 events | 11 (19%) | 5 (26%) | 6 (16%) | |
| Dead | 10 (18%) | 0 (0%) | 10 (26%) |
| . | Total Patients (N = 57) . | MBL-Ec (n = 19) . | Non–MBL-Ec (n = 38) . | P (α = 0.05)a . |
|---|---|---|---|---|
| Clinical response | 39 (68%) | 14 (74%) | 25 (66%) | .76 |
| Disposition after dischargeb | .06 | |||
| Home | 38 (67%) | 16 (84%) | 22 (58%) | |
| Other care facility | 5 (9%) | 2 (11%) | 3 (8%) | |
| Hospice or death | 14 (25%) | 1 (5%) | 13 (34%) | |
| Time from culture to discharge, median days (Q1, Q3) | 18 (7, 25) | 21 (6, 54) | 17.5 (8, 24) | .35c |
| 30-Day mortality | 10 (18%) | 0/19 (0%) | 10/38 (26%) | .02 |
| 90-Day mortality | 15 (26%) | 0/19 (0%) | 15/38 (39%) | .001 |
| DOOR outcomes (30 d) | 62.0% (48.2%-74.3%)d | |||
| Alive without events | 25 (44%) | 10 (53%) | 15 (39%) | |
| Alive with 1 event | 11 (19%) | 4 (21%) | 7 (18%) | |
| Alive with 2 or 3 events | 11 (19%) | 5 (26%) | 6 (16%) | |
| Dead | 10 (18%) | 0 (0%) | 10 (26%) |
Data are presented as n (%).
Abbreviations: DOOR, desirability of outcome ranking; MBL, metallo-β-lactamase; Q, quartile.
Statistical tests performed include chi-square test for categorical variables, except in the case of low expected cell counts when Fisher's exact was used, and Kruskal-Wallis test for differences in distributions for continuous variables. P values compare isolates harboring MBL with those not harboring MBL.
Disposition to “other care facility” includes 3 transfers to another hospital, 1 transfer to long-term care, 1 transfer to long-term acute care.
Kruskal-Wallis test.
DOOR probability (95% confidence interval), or the probability that a randomly selected patient in 1 group would have a better overall outcome than a randomly selected patient in the comparison group.
Clinical Outcomes of Patients With Carbapenemase-Producing Escherichia coli (CP-Ec) Infection
| . | Total Patients (N = 57) . | MBL-Ec (n = 19) . | Non–MBL-Ec (n = 38) . | P (α = 0.05)a . |
|---|---|---|---|---|
| Clinical response | 39 (68%) | 14 (74%) | 25 (66%) | .76 |
| Disposition after dischargeb | .06 | |||
| Home | 38 (67%) | 16 (84%) | 22 (58%) | |
| Other care facility | 5 (9%) | 2 (11%) | 3 (8%) | |
| Hospice or death | 14 (25%) | 1 (5%) | 13 (34%) | |
| Time from culture to discharge, median days (Q1, Q3) | 18 (7, 25) | 21 (6, 54) | 17.5 (8, 24) | .35c |
| 30-Day mortality | 10 (18%) | 0/19 (0%) | 10/38 (26%) | .02 |
| 90-Day mortality | 15 (26%) | 0/19 (0%) | 15/38 (39%) | .001 |
| DOOR outcomes (30 d) | 62.0% (48.2%-74.3%)d | |||
| Alive without events | 25 (44%) | 10 (53%) | 15 (39%) | |
| Alive with 1 event | 11 (19%) | 4 (21%) | 7 (18%) | |
| Alive with 2 or 3 events | 11 (19%) | 5 (26%) | 6 (16%) | |
| Dead | 10 (18%) | 0 (0%) | 10 (26%) |
| . | Total Patients (N = 57) . | MBL-Ec (n = 19) . | Non–MBL-Ec (n = 38) . | P (α = 0.05)a . |
|---|---|---|---|---|
| Clinical response | 39 (68%) | 14 (74%) | 25 (66%) | .76 |
| Disposition after dischargeb | .06 | |||
| Home | 38 (67%) | 16 (84%) | 22 (58%) | |
| Other care facility | 5 (9%) | 2 (11%) | 3 (8%) | |
| Hospice or death | 14 (25%) | 1 (5%) | 13 (34%) | |
| Time from culture to discharge, median days (Q1, Q3) | 18 (7, 25) | 21 (6, 54) | 17.5 (8, 24) | .35c |
| 30-Day mortality | 10 (18%) | 0/19 (0%) | 10/38 (26%) | .02 |
| 90-Day mortality | 15 (26%) | 0/19 (0%) | 15/38 (39%) | .001 |
| DOOR outcomes (30 d) | 62.0% (48.2%-74.3%)d | |||
| Alive without events | 25 (44%) | 10 (53%) | 15 (39%) | |
| Alive with 1 event | 11 (19%) | 4 (21%) | 7 (18%) | |
| Alive with 2 or 3 events | 11 (19%) | 5 (26%) | 6 (16%) | |
| Dead | 10 (18%) | 0 (0%) | 10 (26%) |
Data are presented as n (%).
Abbreviations: DOOR, desirability of outcome ranking; MBL, metallo-β-lactamase; Q, quartile.
Statistical tests performed include chi-square test for categorical variables, except in the case of low expected cell counts when Fisher's exact was used, and Kruskal-Wallis test for differences in distributions for continuous variables. P values compare isolates harboring MBL with those not harboring MBL.
Disposition to “other care facility” includes 3 transfers to another hospital, 1 transfer to long-term care, 1 transfer to long-term acute care.
Kruskal-Wallis test.
DOOR probability (95% confidence interval), or the probability that a randomly selected patient in 1 group would have a better overall outcome than a randomly selected patient in the comparison group.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
